| Literature DB >> 30134533 |
Markus Rotter1,2,3, Stefan Brandmaier4,5,6, Marcela Covic7,8,9, Katarzyna Burek10, Johannes Hertel11, Martina Troll12,13,14, Erik Bader15,16,17, Jonathan Adam18,19,20, Cornelia Prehn21, Birgit Rathkolb22,23,24, Martin Hrabe de Angelis25,26,27, Hans Jörgen Grabe28,29, Hannelore Daniel30, Thomas Kantermann31,32, Volker Harth33, Thomas Illig34,35, Dirk Pallapies36, Thomas Behrens37, Thomas Brüning38, Jerzy Adamski39,40,41, Heiko Lickert42,43,44, Sylvia Rabstein45, Rui Wang-Sattler46,47,48.
Abstract
Night shift work can have a serious impact on health. Here, we assess whether and how night shift work influences the metabolite profiles, specifically with respect to different chronotype classes. We have recruited 100 women including 68 nurses working both, day shift and night shifts for up to 5 consecutive days and collected 3640 spontaneous urine samples. About 424 waking-up urine samples were measured using a targeted metabolomics approach. To account for urine dilution, we applied three methods to normalize the metabolite values: creatinine-, osmolality- and regression-based normalization. Based on linear mixed effect models, we found 31 metabolites significantly (false discovery rate <0.05) affected in nurses working in night shifts. One metabolite, acylcarnitine C10:2, was consistently identified with all three normalization methods. We further observed 11 and 4 metabolites significantly associated with night shift in early and late chronotype classes, respectively. Increased levels of medium- and long chain acylcarnitines indicate a strong impairment of the fatty acid oxidation. Our results show that night shift work influences acylcarnitines and BCAAs, particularly in nurses in the early chronotype class. Women with intermediate and late chronotypes appear to be less affected by night shift work.Entities:
Keywords: chronotypes; metabolomics; night shift work; urine normalization; women’s’ health
Year: 2018 PMID: 30134533 PMCID: PMC6161245 DOI: 10.3390/metabo8030045
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Figure 1Study design and work flow for night shift and day shift comparison. Plot (A) shows an overview for nurses in SW (working both day and night shift) performing two shifts from Monday to Friday in day shift (DS) and night shift (NS) respectively with around a 4 week pause in between the study blocks. Boxes labelled DS indicate working hours in day shift, boxes labelled NS indicate working hours in night shift. Throughout the whole shift and observation period, urine samples were collected (grey boxes). Day 1 to day 4 lasts from 9 p.m. to 9 p.m. the next day and defines the time periods for comparison of day shift and night shift metabolic profiles; Plot (B) demonstrates an overview of the urine sample collection and exclusion, as well as the consecutive statistical and pathway analysis. Exclusion 1 = Exclude participants without information on sleep; Exclusion 2 = Exclude diabetics, vegetarians and participants with extreme sleep apnoea, as well as women working only day shift.
Characteristics of participants. Characteristics of all participants, shift working group (SW) in combined and stratified analyses are shown. Means with standard deviations (SD) or number of phenotypes with percentages are shown for each group. BMI (body mass index). * Chronotype is defined as mid-sleep corrected for sleep debt accumulated over the past work week.
| Clinical Parameters | All Participants | Shift Working Participants (Combined Analysis) | Stratified Analysis | ||
|---|---|---|---|---|---|
| Early Chronotype | Intermediate Chronotype | Late Chronotype | |||
| N | 97 | 68 | 16 | 22 | 30 |
| Chronotype (SD) *, a.m. | 04:02 (01:17) | 04:21 (01:14) | 02:50 (00:43) | 03:59 (00:14) | 05:26 (00:48) |
| Mean age (range), years | 39.5 (25.0–60.0) | 37.2 (25.0–57.0) | 41.3 (25.0–50.0) | 40.5 (25.0–57.0) | 32.5 (25.0–56.0) |
| BMI, kg/m2 | 26.2 (5.2) | 26.2 (5.0) | 26.6 (4.5) | 26.7 (5.5) | 25.7 (5.0) |
| Regular smoker (%) | 27 (27.8) | 26 (38.2) | 3 (18.8) | 10 (45.5) | 13 (43.3) |
| Thyroid disease (%) | 20 (20.1) | 12 (17.6) | 4 (25.0) | 2 (9.1) | 6 (19.4) |
| Hypertension (%) | 16 (16.5) | 10 (14.7) | 2 (12.5) | 3 (13.6) | 5 (16.7) |
| Respiratory disease (%) | 14 (14.4) | 9 (13.4) | 0 (0.0) | 5 (23.8) | 4 (13.3) |
| Cases of Allergy (%) | 53 (54.6) | 37 (54.4) | 6 (37.5) | 11 (50.0) | 20 (66.7) |
| Kidney disease (%) | 2 (2.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Correlation of 44 metabolites concentrations after creatinine-, osmolality- and regression-based normalization. Pearson correlation coefficients of three pairwise comparisons are shown. Non-significant correlations are indicated in bold (Bonferroni cut off; p-values < 1.14 × 10−3). In summary, absolute correlation coefficients > 0.15 reflect a statistical significance.
| Metabolite | Creatinine Normalization vs. Osmolality Normalization | Osmolality Normalization vs. RBN | RBN vs. Creatinine Normalization |
|---|---|---|---|
| C0 | 0.76 | 0.84 | 0.97 |
| C2 | 0.84 | 0.85 | 0.98 |
| C3 | 0.68 | 0.76 | 0.96 |
| C4:1 | 0.93 | 0.93 | 0.99 |
| C5 | 0.73 | 0.89 | 0.93 |
| C5-M-DC | 0.75 | 0.83 | 0.96 |
| C5:1 | 0.62 | 0.79 | 0.93 |
| C5:1-DC | 0.68 | 0.76 | 0.95 |
| C6:1 |
| 0.55 | 0.71 |
| C7-DC | 0.21 | 0.56 | 0.79 |
| C8 | −0.01 | 0.49 | 0.61 |
| C8:1 | 0.70 | 0.72 | 0.96 |
| C9 | 0.65 | 0.77 | 0.93 |
| C10 |
| 0.49 | 0.57 |
| C10:1 | 0.18 | 0.49 | 0.79 |
| C10:2 | 0.74 | 0.82 | 0.96 |
| C12 |
| 0.63 | 0.64 |
| C14 | 0.16 | 0.66 | 0.56 |
| C14:1 | 0.23 | 0.70 | 0.70 |
| C14:1-OH | 0.16 | 0.70 | 0.61 |
| C14:2 |
| 0.64 | 0.62 |
| C14:2-OH |
| 0.61 | 0.57 |
| C16 | 0.47 | 0.78 | 0.77 |
| C16-OH | 0.68 | 0.90 | 0.86 |
| C16:2 | 0.19 | 0.75 | 0.48 |
| C18:2 | 0.32 | 0.76 | 0.49 |
| Arg | 0.33 | 0.44 | 0.80 |
| Gln | 0.44 | 0.50 | 0.86 |
| Gly | 0.64 | 0.60 | 0.92 |
| His | 0.58 | 0.51 | 0.90 |
| Met |
| 0.35 | 0.61 |
| Phe | 0.42 | 0.52 | 0.87 |
| Pro | 0.22 | 0.42 | 0.71 |
| Ser | 0.44 | 0.55 | 0.85 |
| Thr | 0.50 | 0.53 | 0.89 |
| Trp | 0.21 | 0.41 | 0.81 |
| Tyr | 0.48 | 0.49 | 0.88 |
| Val | 0.28 | 0.36 | 0.75 |
| Leu/Isoleu | 0.45 | 0.36 | 0.76 |
| Creatinine | - | 0.20 | - |
| PC ae C38:3 | 0.44 | 0.83 | 0.61 |
| PC ae C38:6 |
| 0.55 | 0.66 |
| SM C24:0 | 0.44 | 0.80 | 0.72 |
| H1 | 0.50 | 0.59 | 0.88 |
Results of 15 metabolites significantly altered by night shift work in combined and chronotype-stratified analysis based on creatinine-normalized values in the fully adjusted model. For each metabolite, the β-estimate, the 95% confidence interval (CI) and false discovery rate (FDR) of the full linear mixed effect model (LMEM) for the comparison of day shift (reference) and night shift are shown. The full linear model was adjusted for chronotype, batch effect, smoking status, age, BMI, thyroid disease status, total years of shift work, day of shift and time since last urination. Significant p-values (FDR < 0.05) in both basic and full LMEM model are indicated in bold. N = Number of nurses; n = Number of urine samples.
| Combined Analysis | Early Chronotype | Intermediate Chronotype | Late Chronotype | |||||
|---|---|---|---|---|---|---|---|---|
| Metabolites | β–Estimate (95% CI) | FDR | β–Estimate (95% CI) | FDR | β-Estimate (95% CI) | FDR | β-Estimate (95% CI) | FDR |
| C5 | 0.09 (0.03, 0.15) |
| 0.24 (0.10, 0.38) |
| −0.02 (−0.12, 0.09) | 0.87 | 0.10 (0.01, 0.19) | 0.12 |
| C7-DC | 0.23 (0.12, 0.35) |
| 0.53 (0.25, 0.81) |
| 0.14 (−0.08, 0.35) | 0.47 | 0.15 (−0.01, 0.31) | 0.23 |
| C8 | 0.15 (0.05, 0.26) |
| 0.51 (0.23, 0.79) |
| 0.00 (−0.21, 0.20) | 0.99 | 0.16 (0.02, 0.29) | 0.12 |
| C10 | 0.18 (0.07, 0.28) |
| 0.57 (0.26, 0.88) |
| 0.05 (−0.15, 0.25) | 0.83 | 0.14 (0.01, 0.27) | 0.12 |
| C10:2 | −0.34 (−0.50, −0.18) |
| −0.22 (−0.69, 0.24) | 0.46 | −0.22 (−0.47, 0.03) | 0.38 | −0.39 (−0.64, −0.14) |
|
| C12 | 0.30 (0.18, 0.42) |
| 0.68 (0.37, 0.99) |
| 0.19 (−0.06, 0.44) | 0.41 | 0.23 (0.09, 0.37) |
|
| C14 | 0.16 (0.04, 0.27) |
| 0.53 (0.19, 0.86) |
| 0.09 (−0.13, 0.32) | 0.66 | 0.04 (−0.10, 0.19) | 0.78 |
| C14:1 | 0.18 (0.07, 0.28) |
| 0.52 (0.23, 0.82) |
| 0.14 (−0.06, 0.35) | 0.45 | 0.04 (−0.09, 0.17) | 0.78 |
| C14:1-OH | 0.21 (0.09, 0.33) |
| 0.58 (0.23, 0.93) |
| 0.20 (−0.04, 0.43) | 0.41 | 0.05 (−0.10, 0.20) | 0.78 |
| C14:2 | 0.18 (0.07, 0.29) |
| 0.50 (0.17, 0.82) |
| 0.13 (−0.07, 0.34) | 0.47 | 0.08 (−0.06, 0.22) | 0.52 |
| C14:2-OH | 0.16 (0.05, 0.28) |
| 0.56 (0.22, 0.91) |
| 0.09 (−0.13, 0.30) | 0.66 | 0.04 (−0.10, 0.18) | 0.81 |
| Gly | 0.16 (0.05, 0.28) |
| −0.09 (−0.35, 0.17) | 0.65 | 0.27 (0.07, 0.46) | 0.10 | 0.21 (0.04, 0.39) | 0.12 |
| Phe | 0.33 (0.20, 0.45) |
| 0.40 (0.03, 0.78) | 8.4 × 10−2 | 0.37 (0.14, 0.60) | 6.9 × 10−2 | 0.32 (0.15, 0.50) |
|
| Ser | 0.15 (0.03, 0.27) |
| −0.06 (−0.35, 0.23) | 0.77 | 0.22 (0.02, 0.43) | 0.29 | 0.17 (−0.02, 0.36) | 0.25 |
| SM C24:0 | 0.23 (0.14, 0.32) |
| 0.48 (0.20, 0.76) |
| 0.14 (−0.04, 0.32) | 0.41 | 0.21 (0.11, 0.31) |
|
Figure 2Results of four selected metabolites of three normalization methods of combined and chronotype-stratified analyses as well as pathways potentially affected by night shift work. Plot (A) shows the β-estimates and associated 95% confidence intervals of four metabolites based on creatinine-, osmolality- and regression based normalization of combined and stratified analysis; Plot (B) shows a Venn diagram of significantly altered metabolites when comparing DS with NS in the combined analysis of three normalization methods. Colours indicate the direction of the observed change (red = increase, green = decrease); Plot (C) depicts an overview for pathways potentially affected by night shift work. OCTN2, cell membrane carrier; CACT, Carnitine acylcarnitine translocase; NAD, Nicotinamide adenine dinucleotide (oxidised); NADH, Nicotinamide adenine dinucleotide (deoxidised); NAM, Nicotinamide; NMN, Nicotinamide mononucleotide; NAMPT, nicotinamide phosphoribosyl transferase; NAMPT, Gene encoding NAMPT.
Metabolites associated with night shift (osmolality- and regression-based normalized values). The table shows β-estimates and false discovery rate (FDR) values for 21 metabolites which are significantly associated with night shift work. The calculations were based on osmolality and regression-based normalizations. The basic LMEM was adjusted for chronotype value and batch effect. The full model was adjusted for chronotype value, batch effect, BMI, age, smoking status, thyroid disease status, total years of shift work, day of shift and time since last urination. Significant FDR values are indicated in bold.
| Osmolality-Normalization | Regression Based Normalization | |||||||
|---|---|---|---|---|---|---|---|---|
| Metabolite | Basic Model | Full model | Basic Model | Full model | ||||
| β-Estimate (95% CI) | FDR | β-Estimate (95% CI) | FDR | β-Estimate (95% CI) | FDR | β-Estimate (95% CI) | FDR | |
| C3 | −0.23 (−0.39, −0.07) |
| −0.25 (−0.42, −0.07) |
| −0.14 (−0.29, 0.02) | 0.17 | −0.15 (−0.32, 0.01) | 0.17 |
| C4:1 | −0.10 (−0.16, −0.04) |
| −0.10 (−0.16, −0.05) |
| −0.07 (−0.12, −0.02) |
| −0.07 (−0.12, −0.02) |
|
| C5-M-DC | −0.26 (−0.37, −0.14) |
| −0.29 (−0.41, −0.16) |
| −0.22 (−0.32, −0.11) |
| −0.24 (−0.35, −0.13) |
|
| C5:1 | −0.27 (−0.42, −0.12) |
| −0.32 (−0.48, −0.16) |
| −0.19 (−0.33, −0.06) |
| −0.25 (−0.39, −0.11) |
|
| C7-DC | −0.05 (−0.21, 0.11) | 0.62 | −0.04 (−0.21, 0.14) | 0.72 | 0.26 (0.10, 0.42) |
| 0.29 (0.12, 0.46) |
|
| C10:2 | −0.49 (−0.65, −0.33) |
| −0.47 (−0.64, −0.30) |
| −0.42 (−0.58, −0.25) |
| −0.39 (−0.57, −0.22) |
|
| C12 | 0.03 (−0.12, 0.19) | 0.72 | 0.06 (−0.11, 0.23) |
| 0.25 (0.09, 0.41) |
| 0.31 (0.14, 0.48) |
|
| C18:2 | −0.19 (−0.34, −0.04) |
| −0.23 (−0.39, −0.07) |
| −0.25 (−0.40, −0.09) |
| −0.32 (−0.48, −0.15) |
|
| Arg | −0.29 (−0.44, −0.15) |
| −0.31 (−0.46, −0.16) |
| −0.20 (−0.36, −0.04) | 6.2 × 10−2 | −0.26 (−0.43, −0.08) |
|
| His | −0.15 (−0.28, −0.03) |
| −0.16 (−0.29, −0.03) |
| −0.03 (−0.15, 0.08) | 0.70 | −0.05 (−0.17, 0.08) | 0.56 |
| Met | −0.23 (−0.38, −0.07) |
| −0.24 (−0.40, −0.08) |
| −0.13 (−0.30, 0.03) | 0.21 | −0.16 (−0.33, 0.02) | 0.18 |
| Phe | 0.00 (−0.15, 0.14) | 0.98 | −0.02 (−0.18, 0.13) | 0.76 | 0.24 (0.09, 0.39) |
| 0.21 (0.06, 0.37) |
|
| Pro | −0.24 (−0.38, −0.09) |
| −0.25 (−0.41, −0.10) |
| −0.05 (−0.19, 0.09) | 0.61 | −0.09 (−0.24, 0.06) | 0.36 |
| Thr | −0.20 (−0.36, −0.05) |
| −0.22 (−0.38, −0.06) |
| −0.09 (−0.23, 0.05) | 0.42 | −0.12 (−0.27, 0.04) | 0.28 |
| Trp | −0.19 (−0.32, −0.06) |
| −0.21 (−0.36, −0.07) |
| −0.01 (−0.12, 0.11) | 0.90 | −0.05 (−0.17, 0.07) | 0.56 |
| Val | −0.18 (−0.33, −0.03) |
| −0.20 (−0.36, −0.04) |
| −0.07 (−0.22, 0.09) | 0.56 | −0.11 (−0.28, 0.05) | 0.31 |
| Leu/Isoleu | −0.25 (−0.40, −0.10) |
| −0.27 (−0.43, −0.11) |
| −0.09 (−0.24, 0.07) | 0.49 | −0.13 (−0.30, 0.04) | 0.28 |
| Creatinine | −0.18 (−0.33, −0.04) |
| −0.19 (−0.34, −0.04) |
| −0.15 (−0.30, 0.00) | 0.12 | −0.18 (−0.34, −0.02) |
|
| PC ae C38:3 | −0.35 (−0.51, −0.18) |
| −0.34 (−0.51, −0.16) |
| −0.57 (−0.74, −0.40) |
| −0.55 (−0.74, −0.37) |
|
| SM C24:0 | 0.05 (−0.07, 0.18) | 0.45 | 0.07 (−0.07, 0.20) | 0.39 | 0.19 (0.06, 0.31) |
| 0.21 (0.08, 0.34) |
|
| H1 | −0.26 (−0.40, −0.11) |
| −0.25 (−0.40, −0.10) |
| −0.20 (−0.36, −0.04) | 0.62 | −0.17 (−0.34, 0.01) | 0.15 |